Information Provided By: 
Fly News Breaks for September 1, 2015
NVAX
Sep 1, 2015 | 11:07 EDT
Empire Asset Management analyst Dr. Cathy Reese started shares of Novavax with a Sell rating and $5 price target. The company seems to "jump on the bandwagon" when a governmental vaccine program is prioritized so that it can gain funding and does not have an "effective path towards future positive earnings," Reese tells investors in a research note. Shares of Novavax are down 40c to $10.37 in morning trading.
News For NVAX From the Last 2 Days
There are no results for your query NVAX
